CAN3001: A long term study of ibrutinib

A phase 3 trial looking at the long-term safety and effectiveness of the medication ibrutinib.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT01804686

Trial aim and background  

This is a long-term, phase 3 extension study with the aim of collecting information on the safety and efficacy of the treatment ibrutinib. It will also allow ongoing access of ibrutinib to participants in completed ibrutinib trials. 

Participants will continue with the dose they were given in the initial study until they are no longer benefitting from it, they withdraw consent, or the study ends, whichever happens first.

Who can enter 

This study is enrolling by invitation only and all participants must be currently participating in an ibrutinib clinical trial which has been completed, and have received ibrutinib for at least 6 months.

Locations 

Recruitment is taking place in the following UK locations:

  • University Hospitals Birmingham NHS Trust, Birmingham
  • Royal Bournemouth Hospital, Bournemouth
  • Colchester Hospital University NHS, Colchester
  • Beatson West of Scotland Cancer Centre, Glasgow
  • St James Institute of Oncology, Leeds
  • Leicester Royal Infirmary, Leicester
  • St Bartholomews Hospital, London
  • University College London Hospitals, London
  • Kings College Hospital, London
  • Christie Hospital, Manchester
  • Nottingham University Hospitals NHS Trust, Nottingham
  • Derriford Hospital, Plymouth
  • Royal Hallamshire Hospital, Sheffield
  • Southampton General Hospital, Southampton
  • Royal Marsden Hospital, Sutton

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT01804686

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.